The emergence of immunotherapy for cancer treatment bears considerable clinical promise.
Nevertheless, many patients remain unresponsive, acquire resistance, or suffer dose …

Highlights•A2AR and hypoxia in TME are important barriers that must be overcome in
cancer immunotherapy.•A2AR on immune cells are critical and non-redundant mediators of …

Unprecedented breakthroughs have been made in cancer immunotherapy in recent years.
Particularly immune checkpoint inhibitors have fostered hope for patients with cancer …

Some anticancer agents induce immunogenic cell death that is accompanied by the
emission of danger signals into the tumor microenvironment, thus attracting and activating …

There is a significant amount of excitement in the scientific community around cancer
immunotherapy, as this approach has renewed hope for many cancer patients owing to …

Introduction: The adenosine pathway plays a key role in modulating immune responses in
health and in disease. In health, anti-inflammatory effects of adenosine balance pro …

Tumor cells use various ways to evade anti‐tumor immune responses. Adenosine, a potent
immunosuppressive metabolite, is often found elevated in the extracellular tumor …

Abstract Immuno-oncology (I/O) research has intensified significantly in recent years due to
the breakthrough development and the regulatory approval of several immune checkpoint …

The G protein‐coupled adenosine A2A receptor (A2AAR) is an important new (potential)
drug target in immuno‐oncology, and for neurodegenerative diseases. Preladenant and its …

The chronic lymphocytic leukemia (CLL) niche is a closed environment where leukemic cells
derive growth and survival signals through their interaction with macrophages and T …